Miranova (Ethinylestradiol, Levonorgestrel)

Ethinylestradiol provides estrogenic activity that feeds back to the hypothalamus and pituitary, while levonorgestrel supplies progestogenic activity that reinforces this feedback. Together they inhibit the release of luteinizing hormone (LH) and follicle‑stimulating hormone (FSH), preventing follicular development and ovulation, and also thicken cervical mucus and alter the endometrium.

The dosing regimen for Miranova is determined by the prescribing healthcare professional. Typically, it is taken as a daily oral tablet according to the prescriber’s instructions, but the exact schedule and any break‑weeks should be confirmed with the treating clinician.

Miranova is contraindicated in pregnancy and is classified as pregnancy category X. It should not be started or continued by women who are pregnant. While limited data exist for breastfeeding, most guidelines advise caution and recommend discussing alternatives with a healthcare provider.

To order Miranova, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Miranova contains standard doses of ethinylestradiol and levonorgestrel, offering efficacy comparable to other second‑generation combined oral contraceptives. Differences among products usually relate to hormone dose, formulation excipients, and specific safety profiles, such as varying impacts on lipid metabolism or acne.

Miranova tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Protect them from excess moisture and direct sunlight to maintain potency throughout the shelf life.

Miranova is taken orally, once daily, preferably at the same time each day. The tablet is swallowed whole with water and should be started on the first day of the menstrual cycle or as directed by a healthcare professional.

Serious risks include venous thromboembolism, stroke, myocardial infarction, severe hypertension, hepatic adenoma, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience symptoms like sudden chest pain, shortness of breath, severe headache, visual changes, or swelling of the legs.

Miranova should not be used by women who are pregnant, have a history of thromboembolic disorders, uncontrolled hypertension, active liver disease, known or suspected breast cancer, or who are smokers over the age of 35. It is also contraindicated in individuals with known hypersensitivity to any component of the tablet.